How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,151 results for

Peripheral Neuropathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. (PubMed)

Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Diabetic peripheral neuropathy (DPN) is a common and severe complication that affects 50% of people with diabetes. Painful DPN is reported to occur in 16% to 24% of people with diabetes. A complete and comprehensive management strategy for the prevention and treatment of DPN, whether painful or not, has not yet been defined.Research into treatment for DPN has been characterised by a series of failed clinical trials (...) , with few noteworthy advances. Strategies that support peripheral nerve regeneration and restore neurological function in people with painful or painless DPN are needed. The amino acid acetyl-L-carnitine (ALC) plays a role in the transfer of long-chain fatty acids into mitochondria for β-oxidation. ALC supplementation also induces neuroprotective and neurotrophic effects in the peripheral nervous system. Therefore, ALC supplementation targets several mechanisms relevant to potential nerve repair

2019 Cochrane

4. Tiny Tips: “TREADMILLS” Peripheral Neuropathy mnemonic

Tiny Tips: “TREADMILLS” Peripheral Neuropathy mnemonic Tiny Tips: “TREADMILLS” Peripheral Neuropathy mnemonic - CanadiEM Tiny Tips: “TREADMILLS” Peripheral Neuropathy mnemonic In , by Sean Patrick February 20, 2018 Peripheral neuropathy is prevalent in up to 2.4% of the general population 1 . It is often characterized by an asymmetric distribution with sensory symptoms following a dermatomal pattern. Initial investigations include a complete blood count (CBC), metabolic panel (electrolytes (...) , glucose, urea, creatinine), and thyroid stimulating hormone (TSH) 2 . There are many causes for peripheral neuropathy, so when considering the etiology, think “TREADMILLS.” T oxins Ethanol, Heavy metals, Tetanus, Organophosphates, Diphtheria R enal Failure E ndocrine Diabetes, Hypothyroidism A cquired Immunodeficiency Syndrome (AIDS) D rugs/ D eficiency Amiodarone, Procainamide, Digoxin, Hydralazine, Statins, Isoniazid, Chloroquine, Misoprostol, Metronidazole, Nitrofurantoin Vitamin B6 deficiency

2018 CandiEM

5. Practice Advisory for the Prevention of Perioperative Peripheral Neuropathies

Practice Advisory for the Prevention of Perioperative Peripheral Neuropathies Practice Advisory for the Prevention of Perioperative Peripheral Neuropathies 2018:An Updated Report by the American Society of Anesthesiologists Task Force on Prevention of Perioperative Peripheral Neuropathies* | Anesthesiology | ASA Publications 4113640588 ASA Publications Log in to access full content You must be logged in to access this feature. ASA members enjoy complimentary access to ASA publications, as well (...) as a variety of educational resources. Non-ASA Members Login Free Practice Parameter | January 2018 Practice Advisory for the Prevention of Perioperative Peripheral Neuropathies 2018: An Updated Report by the American Society of Anesthesiologists Task Force on Prevention of Perioperative Peripheral Neuropathies* Author Notes This article is featured in “This Month in Anesthesiology,” page 1A. This article is featured in “This Month in Anesthesiology,” page 1A. Supplemental Digital Content is available

Full Text available with Trip Pro

2018 American Society of Anesthesiologists

6. Preventing complications and treating symptoms of diabetic peripheral neuropathy

Preventing complications and treating symptoms of diabetic peripheral neuropathy Preventing complications and treating symptoms of diabetic peripheral neuropathy Preventing complications and treating symptoms of diabetic peripheral neuropathy Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, Yeh H, Chelladurai Y, Feldman D, Wilson LM, Robinson KA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation Dy SM, Bennett WL, Sharma R, Zhang A, Waldfogel JM, Nesbit SA, Yeh H, Chelladurai Y, Feldman D, Wilson LM, Robinson KA. Preventing complications and treating symptoms of diabetic peripheral neuropathy. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 187. 2017 Authors' objectives To assess benefits and harms of interventions for preventing diabetic peripheral neuropathy (DPN) complications and treatment

2017 Health Technology Assessment (HTA) Database.

7. Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles

Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles | CADTH.ca CADTH Document Viewer Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles Table of Contents Search this document Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure (...) -Sensing Shoe Insoles June 2017 Summary The SurroSense Rx system is a set of pressure-sensing shoe insoles that connect wirelessly to a proprietary smartwatch and is intended for people with diabetes who have mild to moderate sensory loss associated with diabetic peripheral neuropathy, or nerve damage. By providing real-time alerts about plantar pressure distributions, or the area of pressure between the foot and the surface supporting it, users of the SurroSense Rx system can alter their activities

2017 CADTH - Issues in Emerging Health Technologies

8. Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles

Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles | CADTH.ca CADTH Document Viewer Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure-Sensing Shoe Insoles Table of Contents Search this document Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy Using Pressure (...) -Sensing Shoe Insoles June 2017 Summary The SurroSense Rx system is a set of pressure-sensing shoe insoles that connect wirelessly to a proprietary smartwatch and is intended for people with diabetes who have mild to moderate sensory loss associated with diabetic peripheral neuropathy, or nerve damage. By providing real-time alerts about plantar pressure distributions, or the area of pressure between the foot and the surface supporting it, users of the SurroSense Rx system can alter their activities

2017 CADTH - Issues in Emerging Health Technologies

9. Peripheral Neuropathy

Peripheral Neuropathy Peripheral Neuropathy | ONS Hello [ Name ] ! Renew Membership: Hello [ Name ] ! Renew Membership: Menu Search Peripheral Neuropathy Peripheral neuropathy refers to neurologic dysfunction that occurs outside of the brain and spinal cord. Patients with cancer are at risk for , treatment, or both. Solid tumors can cause neuropathic symptoms and pain by pressing on local nerves. Chemotherapeutic agents that can cause peripheral neuropathy include epothilones, platinum analogs (...) , taxanes, and vinca alkaloids. Among patients treated with anticancer therapies known to increase the risk of peripheral neuropathy, 10%–100% will develop the condition. According to the research, peripheral neuropathy can cause pain and other sensory symptoms as well as patient safety concerns because of changes in dexterity, gait and balance problems, weakness, proprioception, and loss of some motor skills. This topic was updated on May 10, 2017. Likely to Be Effective Effectiveness Not Established

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

10. Magnetic resonance neurography to study peripheral neuropathies

Magnetic resonance neurography to study peripheral neuropathies Magnetic resonance neurography to study peripheral neuropathies Magnetic resonance neurography to study peripheral neuropathies Brito V, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Brito V, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. Magnetic resonance neurography to study peripheral neuropathies. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 497. 2016 Authors' conclusions There is no evidence having shown clinical benefits with the inclusion of magnetic resonance neurography as a diagnostic tool in neuropathies, plexopathies

2016 Health Technology Assessment (HTA) Database.

11. Structure-function relationships in peripheral nerve contributions to diabetic peripheral neuropathy. (PubMed)

Structure-function relationships in peripheral nerve contributions to diabetic peripheral neuropathy. Diabetes mellitus (DM) is a major global health concern, affecting more than 9% of the world population. The most common complication of DM is diabetic peripheral neuropathy (DPN), which leads to neuropathic pain in as many as 50% of patients. Despite its prevalence, there is neither good prevention of nor treatments for DPN, representing a major gap in care for the many who are afflicted

2019 Pain

12. Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations

Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations Chemotherapy-induced peripheral neuropathy (CIPN) is a commonly encountered disease entity following chemotherapy for cancer treatment. Although only duloxetine is recommended by the American Society of Clinical Oncology (ASCO) for the treatment of CIPN in 2014, the evidence of the clinical outcome for new pharmaceutic therapies and non-pharmaceutic treatments has not been clearly determined.To (...) % amitriptyline). The evidence for tricyclic antidepressants was inconclusive as amitriptyline showed no benefit but nortriptyline had insufficient evidence. Further research on CIPN treatment is needed with larger sample sizes, long-term follow-up, standardized outcome measurements, and standardized treatment timing.Chemotherapy-induced neuropathy, peripheral neuropathy, chemotherapy-tumor, neuropathic pain, chronic pain, toxicology, treatment, reduction of pain, level of evidence.

2019 EvidenceUpdates

13. Automated symptom and treatment side effect monitoring for improved quality of life among adults with diabetic peripheral neuropathy in primary care: a pragmatic, cluster, randomized, controlled trial

Automated symptom and treatment side effect monitoring for improved quality of life among adults with diabetic peripheral neuropathy in primary care: a pragmatic, cluster, randomized, controlled trial To evaluate the effectiveness of automated symptom and side effect monitoring on quality of life among individuals with symptomatic diabetic peripheral neuropathy.We conducted a pragmatic, cluster randomized controlled trial (July 2014 to July 2016) within a large healthcare system. We randomized (...) 1834 primary care physicians and prospectively recruited from their lists 1270 individuals with neuropathy who were newly prescribed medications for their symptoms. Intervention participants received automated telephone-based symptom and side effect monitoring with physician feedback over 6 months. The control group received usual care plus three non-interactive diabetes educational calls. Our primary outcomes were quality of life (EQ-5D) and select symptoms (e.g. pain) measured 4-8 weeks after

2019 EvidenceUpdates

14. Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review

Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review Acetyl-L-carnitine (ALC) has shown a neuroprotective effect in patients with peripheral neuropathies of different etiologies. Preclinical studies demonstrated a central anti-nociceptive action, both in neuropathic and nociceptive pain models. The present review aims to provide the knowledge on the efficacy of ALC in patients with painful peripheral neuropathy, based on the evidence. Consistent with the PRISMA statement (...) , authors searched PubMed, Embase and the Cochrane Database of Systematic Reviews for relevant papers, including those issued before April 2018. Two authors independently selected studies for inclusion and data extraction: only trials including patients with a diagnosis of peripheral neuropathy and involving at least 10 patients were considered for the purposes of this review. Fourteen clinical trials were revised, to provide the level of evidence for neuropathy. To assess the global efficacy of ALC

Full Text available with Trip Pro

2019 EvidenceUpdates

15. Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. (PubMed)

Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. Identifying mechanisms of diseases with complex inheritance patterns, such as macular telangiectasia type 2, is challenging. A link between macular telangiectasia type 2 and altered serine metabolism has been established previously.Through exome sequence analysis of a patient with macular telangiectasia type 2 and his family members, we identified a variant in SPTLC1 encoding a subunit of serine palmitoyltransferase (SPT (...) in mice led to increases in levels of retinal deoxysphingolipids and compromised visual function. Deoxysphingolipids caused photoreceptor-cell death in retinal organoids, but not in the presence of regulators of lipid metabolism.Elevated levels of atypical deoxysphingolipids, caused by variant SPTLC1 or SPTLC2 or by low serine levels, were risk factors for macular telangiectasia type 2, as well as for peripheral neuropathy. (Funded by the Lowy Medical Research Institute and others.).Copyright © 2019

2019 NEJM

16. Epidemiology and factors associated with peripheral neuropathy among HIV infected patients in Gondar, Ethiopia: A cross-sectional study. (PubMed)

Epidemiology and factors associated with peripheral neuropathy among HIV infected patients in Gondar, Ethiopia: A cross-sectional study. Antiretroviral therapy has surely increased the life expectancy of people living with HIV. However, long term complications like HIV associated sensory neuropathy has a negative impact on quality of life among people living with HIV (PLHIV). In Ethiopia, lack of data on magnitude of the burden and predictors of HIV associated sensory neuropathy in many (...) , Ethiopia. Brief Peripheral Neuropathy Screening tool validated by AIDs Clinical trial group was used for screening HIV-associated sensory neuropathy. Data were analyzed descriptively and through uni- and multivariate logistic regression.In total 359 adult PLHIV with a mean age of 36.5± 9.07 years participated, their median duration of HIV infection was 60 months (IQR 36-84) and their median CD4 count 143cells/μL (IQR 69.5-201.5). Age above 40 years, anti-tuberculosis regimen, tallness, and exposure

Full Text available with Trip Pro

2019 PLoS ONE

17. Effect of certain trimethoxy flavones on paclitaxel - induced peripheral neuropathy in mice (PubMed)

Effect of certain trimethoxy flavones on paclitaxel - induced peripheral neuropathy in mice The anti - nociceptive effect of 7, 2', 3' - trimethoxy flavone, 7, 2', 4' - trimethoxy flavone, 7, 3', 4' - trimethoxy flavone and 7, 5, 4' - trimethoxy flavone against inflammatory, neurogenic and thermal pain in mice was reported earlier. The present study was designed to investigate the effect of the above trimethoxy flavones in amelioration of peripheral neuropathy induced by paclitaxel.Peripheral (...) neuropathy was induced in mice by administration of a single i.p. dose (10 mg/kg) of paclitaxel. The manifestations of peripheral neuropathy such as tactile allodynia, cold allodynia and thermal hyperalgesia were assessed 24 h later by employing hair aesthesiometer test, acetone bubble test and hot water tail immersion test respectively. Further, the role of inflammatory cytokines like TNF - α, IL - 1β and free radicals in the action of trimethoxy flavones was investigated using in vitro assays.The test

Full Text available with Trip Pro

2018 Integrative medicine research

18. Correction: Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. (PubMed)

Correction: Using time series analysis approaches for improved prediction of pain outcomes in subgroups of patients with painful diabetic peripheral neuropathy. [This corrects the article DOI: 10.1371/journal.pone.0207120.].

Full Text available with Trip Pro

2019 PLoS ONE

19. The risk factors for diabetic peripheral neuropathy: A meta-analysis. (PubMed)

The risk factors for diabetic peripheral neuropathy: A meta-analysis. Diabetic peripheral neuropathy (DPN), the most common chronic complication of diabetes, has become an important public health crisis worldwide. Given that DPN is extremely difficult to treat, determining its risk factors and controlling it at an early stage is critical to preventing its serious consequences and the burden of social disease. Current studies suggest that the risk factors for diabetic peripheral neuropathy (...) a scientific basis for a further understanding of the causes of type 2 diabetes complicated with peripheral neuropathy and the improvement of preventive strategies. The next step is to conduct further high-quality prospective cohort studies to validate this paper's findings.

Full Text available with Trip Pro

2019 PLoS ONE

20. Lipid-lowering drugs (statins) and peripheral neuropathy (PubMed)

Lipid-lowering drugs (statins) and peripheral neuropathy Peripheral neuropathy is a disorder with often unknown causes. Some drugs, including statins, are proposed to be among the causes of peripheral neuropathy. This study aimed at evaluating this condition by electrodiagnostic study among patients who had received statins.This case-control study was conducted in Shiraz, Iran in 2015, and included 39 patients aged 35-55 who had received statins for at least 6 months, and 39 healthy matched (...) controls. Using electrodiagnosis, the sensory and motor wave features (amplitude, latency and nerve conduction velocity) of the peripheral nerves (Median, Ulnar, Tibial, Sural, and Peroneal) were evaluated among the subjects. Data were analyzed using SPSS software and p<0.05 was considered statistically significant.Regarding the occurrence of neuropathy, there were no significant differences in any of the definitions presented for peripheral neuropathy. However, the difference was close to significance

Full Text available with Trip Pro

2018 Electronic physician

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>